Tirzepatide significantly reduced predicted 10-year CVD and T2DM risk. The study in Diabetes, Obesity and Metabolism analyzed three-year SURMOUNT-1 trial data to assess long-term cardiometabolic risk changes.

Adults with obesity and prediabetes were assigned to once-weekly tirzepatide (5, 10, or 15 mg) or placebo for 176 weeks. Validated risk engines estimated 10-year predicted risk for ASCVD, HF, total CVD, and T2DM at baseline and week 176.

Tirzepatide reduced predicted ASCVD risk by 4.6% (5 mg), 7.5% (10 mg), and 9.2% (15 mg) using the ACC/AHA equations. The PREVENT equations showed similar reductions of 3.7%, 6.3%, and 8.8%, whereas placebo groups showed increases of 57.9% and 40.5% (p<0.0001 for all). Type 2 diabetes risk declined by 17.0%, 19.6%, and 19.5% with tirzepatide, compared with 4.3% with placebo (p<0.0001).

These results indicate that tirzepatide significantly lowers long-term predicted cardiovascular and diabetes risk in adults with obesity and prediabetes.